Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks

(2016) Nitesh D. Kuhadiya et al.   DIABETES CARE

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

(2016) Thomas Fremming Dejgaard et al.   Lancet Diabetes & Endocrinology

Type 1 Diabetes Treatment Beyond Insulin

(2016) Lindsay B. Harrison et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study

(2015) Christian S. Frandsen et al.   DIABETES CARE

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

(2014) Keith C. Ferdinand et al.   HYPERTENSION

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

(2014) Conrad Eng et al.   LANCET

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

(2013) Gayatri Sarkar et al.   DIABETES CARE

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study

(2013) K.V.S. Hari Kumar et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus

(2013) Nitesh Kuhadiya et al.   Endocrine Practice

Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes

(2012) Bryan C. Bergman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES CARE

Liraglutide as additional treatment for type 1 diabetes

(2011) Ajay Varanasi et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

(2010) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Effects of Exenatide Alone and in Combination With Daclizumab on  -Cell Function in Long-Standing Type 1 Diabetes

(2009) K. I. Rother et al.   DIABETES CARE